These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8015532)

  • 1. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
    Domke A; Willms B
    Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
    Sieradzki J; Soszyński P
    Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure].
    Heuer LJ; Kaufmann HH
    Dtsch Z Verdau Stoffwechselkr; 1985; 45(2):52-8. PubMed ID: 3924553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy.
    Aubell R; Boehme K; Berchtold P
    Arzneimittelforschung; 1983; 33(9):1314-8. PubMed ID: 6357206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N; Burkert A; Haak T
    Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual effects of a short-term intensified insulin therapy in type 2 diabetic patients with oral drug failure.
    Féry F; Desir D; Mockel J
    Diabete Metab; 1991; 17(6):525-9. PubMed ID: 1809598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification in sucrose tolerance test with acarbose, guargum and their combination in patients with non-insulin dependent diabetes.
    Shah PK; Lakhotia M; Purohit A; Jain SK; Gupta SK; Bhandari P
    J Assoc Physicians India; 1993 Nov; 41(11):703-5. PubMed ID: 8005921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of acarbose as monotherapy in NIDDM patients.
    Deerochanawong C; Serirat S; Kornthong P
    J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
    Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
    J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acarbose, an unduly neglected antidiabetic drug].
    Iványi J; Gyimesi A
    Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sucrose meal on insulin requirement in IDDM and its modulation by acarbose.
    Lecavalier L; Hamet P; Chiasson JL
    Diabete Metab; 1986 Jun; 12(3):156-61. PubMed ID: 3525270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.